CMR Institute works with many organizations who rely on our content to ensure their colleagues have the most up to date information on the Diabetes disease state. Their teams can concentrate their finite time and resources on other initiatives knowing that CMR Institute’s content is always up to date and ready for any employee – new hire to tenured – to ensure they can meet the needs of their customers (and their patients). The U.S. has 37.3 million people who have diabetes and 96 million people aged 18 years and above have prediabetes, according to the National Diabetes Statistics Report. The sheer volume of the population with diabetes makes this a key area of focus for the life sciences industry.
CMR Institute’s disease state training helps develop a deeper understanding of the disease, patient profile, and related information so that professionals and teams can have effective clinical conversations about their products and services internally and externally.
We recently refreshed and updated our Diabetes – Approaches in Disease Management training to the 2023 ADA Standards of Care.
The recent updates to our comprehensive diabetes training includes 15 eModules:
- Diabetes and Hypoglycemia
- Glucose Metabolism and Diabetes
- Types of Diabetes
- Complications of Diabetes
- Screening and Diagnosis of Diabetes
- Diabetes Treatment Principles
- Insulin and Insulin-Combination Therapy
- Oral Antidiabetic Agents
- Monitoring of Diabetes
- Lifestyle Management of Diabetes
- Diabetes Landmark Prevention Studies
- Clinical Data in Diabetes
- Patient Education and Team Management of Diabetes
- Noninsulin Injectable Therapy
- New Treatment Option and Future Directions of Diabetes Management
Updates to these modules are significant and cover many important topics. For example, we made important updates to the ADA Standard of Care, AACE/ACE, and ADA/EASD guidelines, information related to the obesity epidemic and ADA Nutrition Therapy Recommendation, and prediabetes guidelines. We have added and updated information on multiple trials, including the EMPEROR-Preserved, EMPEROR-Reduced, DAPA-HF, PRESERVED-HF, SUSTAIN 6, REWIND, CANVAS, Teplizumab, and PROTECT trials.
Organizations seeking to develop their team’s understanding of diabetes and disease management can include these eModules in their training program. The effectiveness of clinical conversations about products and services with practitioners, hospital networks, and all stakeholders heavily depends on understanding the disease state.